ACAD Acadia Pharmaceuticals Inc. Loading...

Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
? ?
21:01
Aug 02
u/LectureForsaken6782 Reddit r/ValueInvesting
ACAD has zero crippling debt, high margins, and double-digit revenue growth. Solid commercial execution (Nuplazid/Daybue) meets strict value and growth criteria. The author holds a position, noting it surprisingly passes all strict biotech hurdles. Clinical trial risks or regulatory hurdles typical of the biotech sector.
ACAD 1ST
HIGH
20:30
Apr 28 ◎
John Wren Chairman and Chief Executive Officer, Omnicom Group Inc. OMC Q1 FY26 call
Winning Acadia Pharmaceuticals as a new client indicates a significant marketing win in the pharma sector.
ACAD
HIGH

About ACAD Analyst Coverage

Buzzberg tracks ACAD (Acadia Pharmaceuticals Inc.) across 2 sources. 1 bullish vs 0 bearish calls from 2 analysts. Sentiment: predominantly bullish (50%). 2 total trade ideas tracked. Latest voices: u/LectureForsaken6782, John Wren.